This article is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Never start, stop, or change medication without consulting your prescribing physician.
The two main classes
Stimulants (methylphenidate and amphetamine-based medications) are the first-line treatment for ADHD in all major clinical guidelines. They work by directly increasing dopamine and norepinephrine in the brain, take effect within 30–60 minutes, and have the strongest evidence base of any ADHD treatment.
Non-stimulants include several mechanistically different medications: atomoxetine (Strattera), guanfacine (Intuniv), clonidine (Kapvay), viloxazine (Qelbree), and off-label options like bupropion (Wellbutrin). They work through different neurotransmitter systems, typically take weeks to reach full effect, and generally produce moderate (rather than large) effect sizes.
| Feature | Stimulants | Non-Stimulants |
|---|---|---|
| Time to effect | 30-60 minutes | 2-8 weeks |
| Typical effect size | 0.7-0.9 (large) | 0.4-0.6 (moderate) |
| Coverage | During active dose only | 24-hour continuous |
| Crash/rebound | Possible | None |
| Controlled substance | Yes (Schedule II) | No |
| Abuse potential | Low at prescribed doses, but present | None |
| Appetite effects | Significant suppression | Variable (some nausea initially) |
| Response rate | ~70% | ~50-60% |
When non-stimulants are the right choice
Non-stimulants aren't "lesser" medications — they serve different clinical situations:
- Comorbid anxiety: Atomoxetine may treat both ADHD and anxiety symptoms (Kratochvil et al., 2005). Some stimulants can worsen anxiety.
- Substance use disorder history: No misuse potential removes a risk factor from treatment.
- Tic disorders: Alpha-2 agonists (guanfacine, clonidine) can improve both ADHD and tics.
- Intolerable stimulant side effects: Some people can't tolerate the appetite suppression, insomnia, or cardiovascular effects of stimulants.
- Evening/morning coverage gaps: 24-hour non-stimulant coverage fills the times stimulants don't reach.
- Combination therapy: Non-stimulants are sometimes added to stimulants to extend coverage or address specific symptoms (e.g., guanfacine for emotional dysregulation or sleep).
The clinical decision process
Most guidelines (including NICE, AAP, and CADDRA) recommend trying a stimulant first unless there's a specific reason not to. If the first stimulant doesn't work, switching to the other stimulant class (methylphenidate ↔ amphetamine) is tried before moving to non-stimulants. This isn't because non-stimulants are bad — it's because stimulants have a higher probability of producing a meaningful response.
However, some prescribers start with non-stimulants when clinical judgment supports it, and this is entirely reasonable. Patient preference, comorbid conditions, and lifestyle factors all legitimately influence this decision.
Can you combine them?
Yes, combination therapy is common in clinical practice. Typical combinations:
- Stimulant (for daytime focus) + guanfacine (for emotional regulation and/or sleep)
- Stimulant + atomoxetine (for 24-hour coverage with peak daytime boost)
Wilens et al. (2009) found that augmenting stimulants with guanfacine produced additional symptom improvement in children who had a partial response to stimulants alone.
References
- Cortese et al. (2018). Comparative efficacy. The Lancet Psychiatry, 5(9).
- Kratochvil et al. (2005). Atomoxetine and comorbid anxiety. JAACAP.
- Wilens et al. (2009). Guanfacine augmentation. JAACAP.